Document is current
Any future updates will be listed below
-
Authors
Ostau, Nicola Edith von
Handke, Analena Elisa https://orcid.org/0009-0000-9472-8956
Wiesenfarth, Manuel
Albers, Peter
Antoch, Gerald
Noldus, Joachim
Reis, Henning
Cotarelo, Cristina
Preetz, Julia
Umutlu, Lale
Ingenwerth, Marc
Radtke, Jan Philipp
Hadaschik, Boris
Schimmöller, Lars
Kesch, Claudia
-
Funding
Funding for this research was provided by:
Universitätsklinikum Essen
- License Information
-
More Information
Article History
Received: 22 February 2024
Accepted: 16 August 2024
First Online: 20 September 2024
Declarations
:
: This study protocol was reviewed and approved by the local ethics committee at University Hospital Essen (19-8978-BO) and University Hospital Düsseldorf (2018-227-RetroDEuA) and conducted in accordance with the ethical standards of the Declaration of Helsinki. The participants provided informed written consent before participating in the study.
: Nicola Edith von Ostau congress travel expenses Janssen-Cilag GmbH. Analena Elisa Handke no disclosures. Manuel Wiesenfarth no disclosures. Marc Ingenwerth no disclosures. Henning Reis Honoraria: Roche, Bristol-Myers Squibb, Janssen-Cilag, Novartis, Astra-Zeneca, MCI, CHOP GmbH, Sanofi, Boehringer-Ingelheim, GlaxoSmithKline, Merck, Diaceutics; Advisory boards: Bristol-Myers Squibb, Roche; travel support: Philips, Roche, Bristol-Myers Squibb; funding: Bristol-Myers Squibb. Jan Philipp Radtke: Advisory Boards and Consulting for Astellas, Janssen Pharmaceuticals, Astra Zeneca, Novartis, Saegeling Medizintechnik, Bender Gruppe, Dr Wolf, Beckelmann und Partner. Invited speaker for Apogepha, Astellas, Astra Zeneca, Bayer, Janssen Pharmaceuticals, Novartis, Philips Invivo. Research Funding: AAA/Novartis, Medical Faculty Heinrich-Heine-University Düsseldorf, EAU Research Foundation. Boris Hadaschik: Advisory boards for Astellas, AstraZeneca, Janssen, Bayer, ABX, Lightpoint, Amgen, MSD, Pfizer, Novartis. Invited speaker for Accord, Astellas, Janssen R&D. Honoraria from Uromed. Research funding from AAA/Novartis, Bristol Myers Squibb, and German Research Foundation. Leadership roles for DKG AUO and DGU. Lars Schimmöller no disclosures. Claudia Kesch: Consulting for Apogepha. Invited speaker for Novartis, and Pfizer.Travel support from Janssen R&D, Amgen and Bayer. Research funding from AAA/Novartis, Amgen and Mariana Oncology. All authors declare no conflict of interest regarding this manuscript.
